Loading
Every dated change on the records linked to Resectable stage I to III non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Eighteen-month event-free survival 70.
Median event-free survival not estimable against 15.
A milestone in how this cancer is treated.
Perioperative durvalumab with neoadjuvant platinum chemotherapy improved event-free survival (hazard ratio 0.
DFS HR 0.
5-year disease-free survival 63.
EFS HR 0.
A milestone in how this cancer is treated.
EFS HR 0.
Segmentectomy was superior to lobectomy for overall survival; in the pure-solid subgroup five-year overall survival was 92.
Disease-free survival significantly improved in the overall population; the co-primary endpoint in the PD-L1 50 percent or greater population was not met.
Physical function at five weeks 4.
A milestone in how this cancer is treated.
Postoperative mediastinal radiotherapy did not improve three-year disease-free survival in completely resected N2 disease; mediastinal relapse fell but cardiopulmonary toxicity rose.
IMpower010: adjuvant atezolizumab after platinum chemotherapy improved disease-free survival in resected stage II to IIIA non-small-cell lung cancer, most in tumours with PD-L1 on 1 percent or more of tumour cells (hazard ratio 0.
A milestone in how this cancer is treated.
Lung cancer mortality reduced 20% (NLST) and 24% in men (NELSON).
A milestone in how this cancer is treated.
Hazard ratio for death 0.
A milestone in how this cancer is treated.